Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
about
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyDistinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminRare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to TherapyAllogeneic stem cell transplantation in first complete remissionProgress in acute myeloid leukemiaNext generation sequencing of acute myeloid leukemia: influencing prognosis.Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.Evidence that the Pim1 kinase gene is a direct target of HOXA9Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.Deep profiling of multitube flow cytometry data.PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data.HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristicsIntegrative meta-analysis of differential gene expression in acute myeloid leukemiaFunctional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation.Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutationsMutated NPM1 in patients with acute myeloid leukemia in remission and relapse.Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples.FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer driversMolecular signatures in acute myeloid leukemia.Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohortIdentification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis.FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from IndiaA knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironmentPrognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.Incidence and prognostic impact of DNMT3A mutations in Korean normal karyotype acute myeloid leukemia patients.Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsDetection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemiaMolecular diagnostics in acute leukemias.Inferring the temporal order of cancer gene mutations in individual tumor samplesMechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean PopulationIntegrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.
P2860
Q24602856-377B6722-6E79-4FCD-82E7-80E3D46D7DF7Q24643738-71B823E4-930A-4D03-B188-357599450BCBQ24652323-18AD026A-2DCD-460D-87AA-448417D8B7ACQ26771425-CD6F47EB-1967-44C1-8C65-A14C34DF3EC2Q26996818-77F4CFAF-B484-4786-8D5C-78F3DAA46451Q27024006-9C4D6A1F-2742-4652-9184-F06C8DB71AAAQ27690776-BB620DE5-309D-40C3-8BF5-23501F5F2A83Q27851545-BF92110D-7F9A-4F63-8E15-451CB5B5F55FQ27851642-5D627C5D-0D0B-4E2A-A246-62F0C70D118AQ28507053-2965E7A3-E810-4653-BCA9-47B3F2F0CB82Q30847181-16FBCAC2-024B-4EBC-8F02-E35F74E64572Q30885002-55331D07-FCF7-45D8-A0A1-A203475A0E38Q31108463-DBFE17DB-8754-4DDD-9BB0-E672414DC5BEQ33249914-C30F237B-1D53-4FEA-9FE0-F3AEFC67CCFAQ33538043-1109E83B-E2E3-45E1-B5AB-56BD78B71477Q33737486-65305313-B89B-4C59-AAA4-5193B8943C5BQ33772702-72129C5A-0632-486B-8E8B-B81F8677F584Q33800539-298EC190-C021-4C37-B666-0B62F708C16DQ34084839-E2250CC3-CB21-479E-975F-AB45BA6FE02AQ34086334-2E7C4CD1-C2C9-48A6-BC39-9606A2BF871AQ34144877-F42D4A3D-51EA-4BA4-ABC8-969460DC676BQ34176732-2F317C71-E849-4245-B9A8-F4A3DC3A516DQ34323801-DBAC25C0-5CA7-4BC5-AE12-7E7EE7B4903AQ34403639-C5B41D2B-CDC0-4D53-AEF4-FE1CFE888112Q34409299-E3160635-F2EE-4508-A17F-EE49F57D2882Q34489170-375CF38E-3F05-4F7C-BE89-A42B35FAB609Q34494573-16D18C5C-9EC2-4608-AD2C-778E17DF5394Q34505038-6424CEBD-2AA9-4197-8427-045B58E79B41Q34635511-ED1683B4-73A1-4716-BF75-97AE77E11E61Q34667807-2F3D2AE4-7239-4675-9939-5A5F3D5CA262Q34755985-DEF0F3ED-6A7B-4AB6-9977-8365B410D806Q34831106-93B7E8E5-FEE8-4F7D-B513-D3241DD214EEQ34930673-D792E88D-41BF-448F-BD55-6AF4FF603ADEQ35003666-1468D1C7-381D-48AA-BE47-35357EC99A70Q35006113-AB9F7E4A-507B-4017-AAA7-034BA9305430Q35007333-3AE1FB2E-47AF-4997-9D78-76A409025C99Q35106921-93E1FF16-0397-4710-8A80-33AA91D15246Q35125923-4E42CA01-96AC-448C-8750-9C49C11A68BEQ35332017-0C701F46-72C9-4B35-8725-3FA081E0FDCFQ35596909-9B72C28D-7C4D-42CE-BB12-7DB0EF6CB54E
P2860
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Mutations in nucleophosmin (NP ...... rable prognostic significance.
@en
type
label
Mutations in nucleophosmin (NP ...... rable prognostic significance.
@en
prefLabel
Mutations in nucleophosmin (NP ...... rable prognostic significance.
@en
P2093
P1433
P1476
Mutations in nucleophosmin (NP ...... rable prognostic significance.
@en
P2093
André G Uitterlinden
Chantal S Goudswaard
Claudia A J Erpelinck
Maarten A Bijl
Mathijs A Sanders
Peter J M Valk
Roel G W Verhaak
Ruud Delwel
Wendy Hugens
Wim van Putten
P304
P356
10.1182/BLOOD-2005-05-2168
P407
P577
2005-08-18T00:00:00Z